Form 4 for RNAZ Transcode Therapeutics, Inc.
Accepted 2022-06-01 00:00:00 ET · period of report 2022-05-27 · accession 0001104659-22-067099 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-06-01 | 2022-05-27+ | RNAZ | Dudley Robert Michael | CEO, Dir, 10% | P - Purchase | $1.84 | +30.0K | 873.1K | +4% | +$55.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-27 | P | A | 28,000 | $1.84 | 871,114 | D | — | — | |
| 2 | Common | Common Stock | 2022-05-31 | P | A | 2,000 | $1.87 | 873,114 | D | — | — |